Activating mutations of PIK3CA are present in 36% of all breast cancers, significantly enriched within luminal A breast cancers (45%) [1], and function by activating the PI3K/AKT pathway to alter a number of cellular processes, including cell proliferation, differentiation, and survival [30]. The gene discussed is AKT1; the disease is breast cancer.